Visit COVID-19 resources

[Skip to Content]

NEW Defined Guidance for the use of Serum Eye Drops

Nov 29
2017

Ocular Surface Disease with dry eye is a global public-health problem with significant impact on quality of life. Serum Eye Drops (SED) contain many nutritional factors that aid therapeutics. Across the NHS there is variation in practice, inequality of access to SED service and no regulated monitoring of outcome. This guideline sets out defined guidance

  • 29 November 2017

RCOphth and NIHR launch Researcher of the Year Awards 2018

Nov 29
2017

The Royal College of Ophthalmologists and The National Institute for Health Research are pleased to announce the opening for applications of the 2018 RCOphth / NIHR Researcher of the Year awards. Applications are sought from Members and Fellows of the College who are engaged in clinical research in the course of their NHS duties. Clinical

  • 29 November 2017

66% of Clinical Leads surveyed by the RCOphth confirm cataract rationing is restricting access to surgery

Nov 09
2017

Cataract surgery: current limitations to patients accessing treatment Cataract surgery is the most common operation performed, with approximately 400,000 performed per year in the UK and has enormous benefit for patients and their quality of life. It is crucial that patients who will benefit from cataract surgery are able to access it, whether for their

  • 9 November 2017

NICE press release: People at low risk of developing glaucoma can avoid unnecessary referrals

Nov 02
2017

NICE – the National Institute for Health and Care Excellence – has updated its guidance on the diagnosis and management of chronic open angle glaucoma (COAG). The new guideline now includes a section on what tests should be carried out by primary eye care professionals to determine if referral to a specialist is necessary. This

  • 2 November 2017

RCOphth collaborate with the BMJ on latest Avastin editorial

Nov 02
2017

Have you read the BMJ editorial ‘Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?’  We collaborated with the BMJ journalist to support the overall message of a much needed review of the ‘off-label’ status of Bevacizumab (Avastin), particularly in relation to the most recent news from the EU

  • 2 November 2017